FI4214202T3 - Cdk4-estäjän kiinteät muodot - Google Patents
Cdk4-estäjän kiinteät muodot Download PDFInfo
- Publication number
- FI4214202T3 FI4214202T3 FIEP21783049.6T FI21783049T FI4214202T3 FI 4214202 T3 FI4214202 T3 FI 4214202T3 FI 21783049 T FI21783049 T FI 21783049T FI 4214202 T3 FI4214202 T3 FI 4214202T3
- Authority
- FI
- Finland
- Prior art keywords
- cancer
- crystalline form
- ppm
- values
- wavenumber
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078636P | 2020-09-15 | 2020-09-15 | |
| US202163240268P | 2021-09-02 | 2021-09-02 | |
| PCT/IB2021/058320 WO2022058871A1 (en) | 2020-09-15 | 2021-09-13 | Solid forms of a cdk4 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4214202T3 true FI4214202T3 (fi) | 2025-04-25 |
Family
ID=78000744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21783049.6T FI4214202T3 (fi) | 2020-09-15 | 2021-09-13 | Cdk4-estäjän kiinteät muodot |
Country Status (18)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022002415A (es) | 2019-08-26 | 2022-03-22 | Arvinas Operations Inc | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. |
| KR20240112931A (ko) * | 2021-12-02 | 2024-07-19 | 화이자 인코포레이티드 | 암 치료를 위한 cdk4 억제제 |
| KR20250040736A (ko) | 2022-07-29 | 2025-03-24 | 화이자 인코포레이티드 | 암의 치료를 위한 kat6 억제제를 포함하는 투여 요법 |
| CN120981721A (zh) | 2023-03-30 | 2025-11-18 | 辉瑞大药厂 | Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法 |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| WO2024246825A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Combinations of estrogen receptor degraders and cdk4 inhibitors |
| WO2024246824A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| TW202513069A (zh) | 2023-07-21 | 2025-04-01 | 美商冰洲石生物科技公司 | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 |
| WO2025104624A1 (en) | 2023-11-14 | 2025-05-22 | Pfizer Inc. | Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2025202900A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors for use in the treatment of mantle cell lymphoma |
| WO2025202871A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| EP3484871B1 (en) * | 2016-07-13 | 2023-06-07 | Syros Pharmaceuticals, Inc. | Piperidine derivatives as inhibitors of cyclin dependent kinase 7 (cdk7) |
| CR20190062A (es) | 2016-08-15 | 2019-05-22 | Pfizer | Inhibidores de cdk2/4/6 |
| RS66650B1 (sr) | 2018-04-26 | 2025-04-30 | Pfizer | 2-amino-piridin ili 2-amino-pirimidin derivati kao inhibitori kinaza zavisnih od clklina |
-
2021
- 2021-09-13 WO PCT/IB2021/058320 patent/WO2022058871A1/en not_active Ceased
- 2021-09-13 DK DK21783049.6T patent/DK4214202T3/da active
- 2021-09-13 EP EP25153633.0A patent/EP4578450A3/en active Pending
- 2021-09-13 SI SI202130288T patent/SI4214202T1/sl unknown
- 2021-09-13 ES ES21783049T patent/ES3022913T3/es active Active
- 2021-09-13 US US18/245,039 patent/US20230357211A1/en active Pending
- 2021-09-13 CA CA3195063A patent/CA3195063A1/en active Pending
- 2021-09-13 CN CN202180071477.7A patent/CN116507620B/zh active Active
- 2021-09-13 EP EP21783049.6A patent/EP4214202B1/en active Active
- 2021-09-13 MX MX2023003054A patent/MX2023003054A/es unknown
- 2021-09-13 HU HUE21783049A patent/HUE070846T2/hu unknown
- 2021-09-13 PL PL21783049.6T patent/PL4214202T3/pl unknown
- 2021-09-13 JP JP2021148619A patent/JP7260606B2/ja active Active
- 2021-09-13 FI FIEP21783049.6T patent/FI4214202T3/fi active
- 2021-09-13 AU AU2021345531A patent/AU2021345531B2/en active Active
- 2021-09-13 PT PT217830496T patent/PT4214202T/pt unknown
- 2021-09-13 KR KR1020237012766A patent/KR20230069983A/ko not_active Ceased
- 2021-09-14 TW TW112102545A patent/TW202334125A/zh unknown
- 2021-09-14 TW TW110134168A patent/TWI809503B/zh active
-
2022
- 2022-10-27 JP JP2022172594A patent/JP7291839B2/ja active Active
-
2023
- 2023-03-16 ZA ZA2023/03655A patent/ZA202303655B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI4214202T1 (sl) | 2025-05-30 |
| JP2022186995A (ja) | 2022-12-15 |
| JP7260606B2 (ja) | 2023-04-18 |
| DK4214202T3 (da) | 2025-03-31 |
| EP4214202B1 (en) | 2025-02-26 |
| MX2023003054A (es) | 2023-04-05 |
| CN116507620A (zh) | 2023-07-28 |
| PT4214202T (pt) | 2025-04-11 |
| JP2022049005A (ja) | 2022-03-28 |
| CN116507620B (zh) | 2025-11-18 |
| ZA202303655B (en) | 2024-09-25 |
| TW202216698A (zh) | 2022-05-01 |
| US20230357211A1 (en) | 2023-11-09 |
| EP4578450A3 (en) | 2025-07-16 |
| PL4214202T3 (pl) | 2025-05-19 |
| AU2021345531B2 (en) | 2024-02-29 |
| WO2022058871A1 (en) | 2022-03-24 |
| TWI809503B (zh) | 2023-07-21 |
| EP4578450A2 (en) | 2025-07-02 |
| BR112023004713A2 (pt) | 2023-04-18 |
| ES3022913T3 (en) | 2025-05-29 |
| KR20230069983A (ko) | 2023-05-19 |
| AU2021345531A1 (en) | 2023-04-20 |
| HUE070846T2 (hu) | 2025-07-28 |
| CA3195063A1 (en) | 2022-03-24 |
| JP7291839B2 (ja) | 2023-06-15 |
| EP4214202A1 (en) | 2023-07-26 |
| TW202334125A (zh) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4214202T3 (fi) | Cdk4-estäjän kiinteät muodot | |
| JP2022049005A5 (cg-RX-API-DMAC7.html) | ||
| JP2022186995A5 (cg-RX-API-DMAC7.html) | ||
| HRP20100166T1 (hr) | Postupak za pripremu 2-aminotiazol-5-aromatičnih karboksamida kao inhibitora kinaze | |
| MX2020005363A (es) | Compuestos heterociclicos como inhibidores de prmt5. | |
| FI2534153T4 (fi) | 8-fluori-2-{4-[(metyyliamino}metyyli]fenyyli}-1,3,4,5-tetrahydro-6h-atsepino[5,4,3-cd]indol-6-onin suoloja ja polymorfeja | |
| FI2134702T4 (fi) | 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen | |
| WO2012042539A3 (en) | 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders | |
| JP2015512942A5 (cg-RX-API-DMAC7.html) | ||
| FI3694863T3 (fi) | Lorlatinibin vapaan emäksen hydraatin kidemuoto | |
| JP2012526808A5 (cg-RX-API-DMAC7.html) | ||
| MX2023009857A (es) | Inhibidores de la glucogeno sintasa 1 (gys1) y metodos de uso de los mismos. | |
| HRP20171895T1 (hr) | Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline | |
| KR101129088B1 (ko) | Ｎ-［6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일］-2-메틸-4'-(트리플루오로메톡시)［1,1'-비페닐］-3-카르복스아미드의 염 | |
| EA200800516A1 (ru) | Производные n-фенил-2-пиримидинамина и процесс их получения | |
| IL197262A0 (en) | Anti cancer use of caffeic acid and its derivatives | |
| HRP20171041T1 (hr) | Nova sol abeksinostata, s njome povezani kristalni oblik, postupak pripreme i farmaceutske tvari koje ih sadrže | |
| JP2016504325A5 (cg-RX-API-DMAC7.html) | ||
| JP2015502371A5 (cg-RX-API-DMAC7.html) | ||
| HRP20140409T1 (hr) | Derivat imidazola sa strukturom prolinskog prstena | |
| FI3317264T3 (fi) | (S)-[3,4-difluori-2-(2-fluori-4-jodifenyyliamino)fenyyli][3-hydroksi-3-(piperidin-2-yyli)atsetidin-1-yyli]metanonin kiteinen fumaraattisuola | |
| JP4707393B2 (ja) | 抗癌化合物 | |
| WO2008087514A3 (en) | Hdac inhibitors | |
| AU2020348825B2 (en) | Heterocyclic amide compound, pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof | |
| CN115397815A (zh) | 稠合二环类衍生物、其制备方法及其在医药上的应用 |